Treatment of Ebola virus disease
- Authors: Zhdanov K.V1, Shchegolev A.V1, Kovalenko A.N1, Zakharenko S.M1, Klimov A.G1
-
Affiliations:
- Issue: Vol 336, No 11 (2015)
- Pages: 48-53
- Section: Articles
- URL: https://journals.eco-vector.com/0026-9050/article/view/74035
- DOI: https://doi.org/10.17816/RMMJ74035
- ID: 74035
Cite item
Abstract
The article presents data on the etiology, pathogenesis, clinical presentation, diagnosis and modern approaches to the treatment of Ebola haemorrhagic fever. This serious infectious disease with a high fatality rate is characterized by intoxication, severe haemorrhages, disseminated intravascular coagulation, and multiple organ failure with the development of severe shock. It is emphasized that the treatment of patients with Ebola should be conducted under strict anti-epidemic regime. Since there is currently no effective drugs against Ebola virus, the basis of modern treatment of this disease are pathogenic and symptomatic treatments. The main activities should be aimed at correcting violations homeostasis, blood volume deficiency, disorders of water and electrolyte balance, acid-base status osmolar and oncotic pressure shortfall of clotting factors and blood components. The treatment program should be drawn up taking into account the stage of the disease, the severity of the course and comorbidity.
Full Text
About the authors
K. V Zhdanov
Email: ZhdanovKV@rambler.ru
A. V Shchegolev
A. N Kovalenko
S. M Zakharenko
A. G Klimov
References
- Bellan S.E., Pulliam J.R.C., Dushoff J., Meyers L.A. Ebola control: effect of asymptomatic infection and acquired immunity // The Lancet. - 2014, Vol. 384, Iss. 9953. - P. 1499-1500.
- Burnouf T., Seghatchian J. Ebola virus convalescent blood products: Where we are now and where we may need to go. URL: http://www. researchgate.net (дата обращения: 26.08.2015).
- Centers for Disease Control and Prevention. Bioterrorism Agents/ Diseases. URL: http://www. bt.cdc.gov (дата обращения: 26.08.2015).
- Feldmann H., Geisbert T.W. Ebola haemorrhagic fever // The Lancet. - 2011. - Vol. 377, Iss. 9768. - P. 849-862.
- Folayan M., Brown B., Yakubu A. et al. Compassionate use of experimental drugs in the Ebola outbreak // The Lancet. - 2012. - Vol. 384, Iss. 9957. - P. 1843-1844.
- Geisbert T.W. Marburg and Ebola haemorrhagic fever (Filoviruses) / Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Eighth edition. - 2015. - Elsevier: Philadelphia, USA. - Vol. II. - P. 1995-1999.
- Geisbert T.W., Young H.A., Jahrling P.B. et al. Pathogenesis of Ebola haemorrhagic fever in primate models: evidence that haemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells // Am. J. Pathol. - 2003. - Vol. 163. - P. 2371-382.
- Rid A., Emanuel E.J. Compassionate use of experimental drugs in the Ebola outbreak - Authors’ reply // The Lancet. 2012. - Vol. 384, Iss. 9957. - P. 1844.
- Roddy P., Howard N., Van Kerkhove M.D. et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. URL: http://www.ncbi.nlm.nih.gov (дата обращения: 26.08.2015).